| 11/16/2026 5:01 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Cellectar Biosciences (1279704) Subject | Form SCHEDULE 13G/A | |
| 11/10/2026 6:25 AM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/10/2026 5:55 AM | Cellectar Biosciences (1279704) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/14/2026 11:11 AM | Cellectar Biosciences (1279704) Subject SILVERARC CAPITAL MANAGEMENT, LLC (1816307) Filed by | Form SCHEDULE 13G | |
| 08/14/2026 11:00 AM | Cellectar Biosciences (1279704) Subject STEMPOINT CAPITAL LP (1952142) Filed by | Form SCHEDULE 13G | |
| 08/14/2026 5:02 AM | BALYASNY ASSET MANAGEMENT L.P. (1218710) Filed by Cellectar Biosciences (1279704) Subject | Form SCHEDULE 13G | |
| 08/13/2026 6:25 AM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/13/2026 6:00 AM | Cellectar Biosciences (1279704) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 08/04/2026 9:06 AM | Cellectar Biosciences (1279704) Subject Empery Asset Management, LP (1469336) Filed by | Form SCHEDULE 13G | |
| 07/10/2026 8:00 PM | Cellectar Biosciences (1279704) Issuer Loren Stefan (1441500) Reporting | Form 4/A | |
| 07/10/2026 4:13 PM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for CLRB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/08/2026 8:07 PM | CARUSO JAMES V (1202770) Reporting Cellectar Biosciences (1279704) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:09 PM | Cellectar Biosciences (1279704) Issuer Chanan-Khan Asher (1869837) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:10 PM | Cellectar Biosciences (1279704) Issuer DRISCOLL FREDERICK W (1129890) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:13 PM | Cellectar Biosciences (1279704) Issuer Kolean Chad J (1616753) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:00 PM | Cellectar Biosciences (1279704) Issuer Loren Stefan (1441500) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:02 PM | Cellectar Biosciences (1279704) Issuer NEIS JOHN (1167426) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:04 PM | Cellectar Biosciences (1279704) Issuer Swirsky Douglas J (1375884) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:05 PM | Cellectar Biosciences (1279704) Issuer Longcor Jarrod (1545565) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 07/08/2026 8:06 PM | Cellectar Biosciences (1279704) Issuer Gu Andrew (2137966) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:00 PM | Cellectar Biosciences (1279704) Issuer Gu Andrew (2137966) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/05/2026 11:56 AM | Cellectar Biosciences (1279704) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G | |
| 06/01/2026 11:15 PM | Cellectar Biosciences (1279704) Filer | Form EFFECT | |
| 06/02/2026 5:01 AM | Cellectar Biosciences (1279704) Filer | Form 424B3 | |
| 05/29/2026 7:50 AM | Cellectar Biosciences (1279704) Filer | Form S-1/A | |
| 05/28/2026 4:13 PM | Cellectar Biosciences (1279704) Filer | Form DEF 14A | |
| 05/28/2026 4:14 PM | Cellectar Biosciences (1279704) Filer | Form DEFA14A | |
| 05/19/2026 4:05 PM | Cellectar Biosciences (1279704) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 05/18/2026 4:00 PM | Cellectar Biosciences (1279704) Filer | Form PRE 14A | |
| 05/18/2026 3:15 PM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 6:20 AM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/14/2026 6:00 AM | Cellectar Biosciences (1279704) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 7:05 PM | CARUSO JAMES V (1202770) Reporting Cellectar Biosciences (1279704) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 7:07 PM | Cellectar Biosciences (1279704) Issuer Longcor Jarrod (1545565) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/11/2026 6:05 PM | Cellectar Biosciences (1279704) Subject Stonepine Capital Management, LLC (1440771) Filed by | Form SCHEDULE 13G | |
| 05/08/2026 5:04 AM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 10:48 AM | Cellectar Biosciences (1279704) Filer | Form 424B5 | |
| 04/30/2026 3:51 PM | Cellectar Biosciences (1279704) Filer | Form 10-K/A | |
| 03/04/2026 6:21 AM | Cellectar Biosciences (1279704) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/04/2026 6:23 AM | Cellectar Biosciences (1279704) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 02/13/2026 3:44 PM | Bleichroeder LP (1781002) Filed by Cellectar Biosciences (1279704) Subject | Form SCHEDULE 13G/A | |
The Democrats can’t stop this (Ad) Porter Stansberry believes President Trump has begun a full dollar reset through executive order 14241, bypassing Congress under a national emergency.
His new briefing outlines three steps to prepare and names a core group of assets tied to the initiative that he says could surge.
He points to the 1970s Nixon-era reset, which reportedly minted an average of 1,300 new millionaires a day for over half a century. Get Porter Stansberry's briefing on Trump's new dollar and the three steps he outlines. |
| 02/10/2026 2:23 PM | Cellectar Biosciences (1279704) Subject Rosalind Advisors, Inc. (1622627) Filed by | Form SCHEDULE 13G/A | |
| 02/04/2026 3:11 PM | Cellectar Biosciences (1279704) Subject Hexstone Capital LLC (2066973) Filed by | Form SCHEDULE 13G/A | |
| 12/16/2025 5:00 PM | Cellectar Biosciences (1279704) Issuer NEIS JOHN (1167426) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 11/21/2025 3:05 PM | Cellectar Biosciences (1279704) Filer | Form 424B3 | |